Detalles de la búsqueda
1.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35112166
2.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35230585
3.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27979383
4.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 565, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35507135
5.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
N Engl J Med
; 362(22): 2053-65, 2010 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-20519679
6.
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
Breast Cancer Res Treat
; 142(2): 415-21, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24202240
7.
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Br J Haematol
; 154(4): 477-81, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21707581
8.
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Lancet
; 373(9669): 1097-104, 2009 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-19303137
9.
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
J Clin Oncol
; 38(5): 444-453, 2020 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821109
10.
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Lung Cancer
; 55(2): 187-94, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17092602
11.
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Clin Breast Cancer
; 17(1): 48-54.e3, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27693116
12.
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
J Clin Oncol
; 35(35): 3942-3948, 2017 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29072977
13.
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
J Clin Oncol
; 35(1): 40-47, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28034081
14.
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
J Clin Oncol
; 34(25): 3005-13, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27400947
15.
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
J Clin Oncol
; 22(23): 4753-61, 2004 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15570076
16.
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
Clin Lung Cancer
; 7(1): 40-6, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16098243
17.
Organizational barriers to physician participation in cancer clinical trials.
Am J Manag Care
; 11(7): 413-21, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16044978
18.
Body weight correlates with mortality in early-stage breast cancer.
Arch Surg
; 139(9): 954-58; discussion 958-60, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15381612
19.
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
J Clin Oncol
; 31(31): 3926-34, 2013 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24101054
20.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
J Clin Oncol
; 31(26): 3197-204, 2013 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23940225